Drug Trial Radar · NCT03272165
Single Ascending Dose Study of MEDI1341 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jun 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Oct 17, 2017
Primary completion
Mar 31, 2021
Study completion Mar 31, 2021
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Covance; MMS Holdings, Inc; Catalent; Takeda
- First posted
- Sep 5, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a study of single ascending intravenous doses of MEDI1341 or placebo in up to 48 healthy volunteers, aged 18 to 65 years. The study will include up to 6 planned cohorts; each cohort will comprise 8 participants. Each participant will receive a single 60 minute intravenous infusion of MEDI1341 or placebo and will undergo scheduled assessments over a period of 13 weeks. The main aim of the study is to assess the safety and tolerability of single doses of MEDI1341 in healthy volunteers.
Conditions
- Parkinson's Disease
Interventions
MEDI1341Drug
Participants will receive IV infusion of MEDI1341 doses as stated in the arms' description.
PlaceboDrug
Participants will receive IV infusion of placebo matched to MEDI1341.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Time frame: Day 1 through 92 days after a single dose of study drug
- Number of Participants With Abnormal Vital Signs, Physical and Neurological Examinations, and Body Weight Measurements Reported as TEAEsTime frame: Day 1 through 92 days after a single dose of study drug
- Change from Baseline in 12-Lead Electrocardiogram (ECG) Data in Paper and Digital Recordings (PR Interval, QRS Duration, QT Interval, QTcF Interval, and RR Interval)Time frame: 12-lead paper ECG: Baseline (Day -49) to Day 92; Digital ECG: Baseline (Day 1) to Day 92
- Change from Baseline in Heart Rate by 12-Lead ECG in Paper and Digital RecordingsTime frame: 12-lead paper ECG: Baseline (Day -49) to Day 92; Digital ECG: Baseline (Day 1) to Day 92
- Number of Participants With Abnormal Laboratory Parameters Reported as TEAEsTime frame: Day 1 through 92 days after a single dose of study drug
- Number of Abnormal Findings for Ophthalmic Assessment (Ophthalmic Examination and Slit-lamp Examination) for Placebo and Cohorts 4 to 6 at Follow-up VisitTime frame: Follow-up Visit (Day 57)
- Intraocular Pressure at Screening for Placebo and Cohorts 4 to 6Time frame: Screening (Day -49)
- Intraocular Pressure at Day 29 for Placebo and Cohorts 4 to 6Time frame: Day 29
- Intraocular Pressure at Day 92 for Placebo and Cohorts 4 to 6Time frame: Day 92
- Number of Participants With Injection Site ReactionsTime frame: Day 1
- Visual Analogue Scale (VAS) Pain Score for Site Reaction PainTime frame: Day 1 (within 24 hours after end of infusion)
- Number of Participants With Suicidal Ideation and Suicidal Behavior Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: Screening (Day -49) through 92 days after a single dose of study drug
- Number of Participants With Montreal Cognitive Assessment (MoCA) Total Score at Screening (Day -1)Time frame: Screening (Day -1)
- Number of Participants With MoCA Total Score at Day 92Time frame: Day 92
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Dallas, Texas
Research Site
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.